Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

[18f]mk-0947

Phase 1

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Parkinson's Disease (PD)Recruiting

Parkinson's Disease (PD)Phase 1

Recruiting

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Parkinson's Disease (PD)

NCT07348250

Clinical

Trials by Indication[1]

Parkinson's Disease (PD)1 trial

An Open-label Study to Evaluate Brain α-Synuclein Deposition Using Positron Emission Tomography (PET) and [18F]MK-0947 in Patients With Parkinson's Disease

Recruiting·IInvicro·Phase 1·NCT07348250·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for [18f]mk-0947. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for [18f]mk-0947. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Invicro company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: IInvicro

Related News